Lifitegrast Ophthalmic Solution Market Estimated to Expand at a Robust CAGR by 2024
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in the eye. Across the world, over 300 million people are...
View full press release